US Pharma MarketingThe post EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s appeared first on Clinical Trials Arena.
EAN 2026: Real-world data supports safety and efficacy of AbbVie's Vyalev in Parkinson's
The real-world data study tracked Parkinson's disease patients for 12 months during treatment with AbbVie's Vyalev The real-world data study tracked Parkinson's disease patients for 12 months during treatment with AbbVie's Vyalev AbbVie gained approval for Vyalev in the US in October 2024. Credit: Skorzewiak / Shutterstock.com AbbVie’s ROSSINI (NCT06107426) study of its Parkinson’s disease combination, Vyalev, has shown promise in a 12-month analysis. The data, which was presented on 29 June at the 12 th Congress of the European Academy of Neurology (EAN) 2026, supported the safety and effectiveness of Vyalev (foslevodopa/foscarbidopa [LDp/CDp]), a nonsurgical, 24-hour/day continuous subcutaneous infusion…
The real-world data study tracked Parkinson's disease patients for 12 months during treatment with AbbVie's Vyalev
Source: Clinical Trials Arena